Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 5008-5016

  Pugh, Trevorj ^a   Keyes, Mira ^a   Barclay, Lorena ^a   Delaney, Allen ^a   Krzywinski, Martin ^a   Thomas, Dallas ^a   Novik, Karen ^a   Yang, Cindy ^a   Agranovich, Alexander ^a   McKenzie, Michael ^a   Morris, W Jim ^a   Olive, Peggy L ^a   Marra, Marcoa ^a   Moore, Richard A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; GENOMIC DNA; RAD50 PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

AMPLICON; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DNA REPAIR; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MALE; MISSENSE MUTATION; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RADIOSENSITIVITY;

BRACHYTHERAPY; DNA REPAIR; EXONS; HUMANS; MALE; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE;

EID: 68049123415     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3357     Document Type: Article

References (42)

1. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001;51: 31-40.
2. Potters L, Morgenstern C, Calugaru E, et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562-1566 (Pubitemid 40524771)
3. Morris WJ, Keyes M, Palma D, et al. Population-based study of biochemical and survival outcomes after permanent (125)I brachytherapy for low- and intermediate- risk prostate cancer.Urology 2009;4:860-865
4. Keyes M, Miller S, Moravan V, et al. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-termout come in 712 consecutive patients. Int J Radiat Oncol Biol Phys 2008;73:1023-1032
5. Bucci J, Morris WJ, Keyes M, Spadinger I, Sidhu S, Moravan V. Predictive factors of urinary retention following prostate brachytherapy. Int JRadiat Oncol Biol Phys 2002;53:91-98 (Pubitemid 34465811)
6. Keyes M, Schellenberg D, Moravan V, et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve? Int J Radiat Oncol Biol Phys 2006;64:825-834
7. Keyes M, Miller S, Moravan V, et al. Acute and late urinary toxicity in 606 prostate brachytherapy patients. Radiother Oncol 2006;80:S41-2.
8. Keyes M, Moravan V, Liu M, Jankovic B, Morris WJ. Rectal toxicity after I125 permanent. Radiother Oncol 2005;76:S5-6.
9. Macdonald AG, Keyes M, Kruk A, Duncan G, Moravan V, Morris WJ. Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: is dose to the penile bulb important? Int J Radiat Oncol Biol Phys 2005;63:155-163
10. Bottomley D, Ash D, Al-Qaisieh B, et al. Side effects of permanent I125 prostate seed implants in 667 patients treated in Leeds. Radiother Oncol 2007;82: 46-49 (Pubitemid 46097133)
11. Lehrer S, Cesaretti J, Stone NN, Stock RG. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJU Int 2006; 98:979-981 (Pubitemid 44536443)
12. Wust P, von Borczyskowski DW, Henkel T, et al. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiother Oncol 2004; 73:39-48. (Pubitemid 39304123)
13. Finnon P, Robertson N, Dziwura S, et al. Evidence for significant heritability of apoptotic and cell cycle responses to ionising radiation. Hum Genet 2008; 123:485-493
14. Roberts SA, Spreadborough AR, Bulman B, Barber JB, Evans DG, Scott D. Heritability of cellular radiosensitivity: a marker of low-penetrance predisposition genes in breast cancer? Am J Hum Genet 1999;65: 784-794
15. Burrill W, Barber JB, Roberts SA, Bulman B, Scott D. Heritability of chromosomal radiosensitivity in breast cancer patients: a pilot study with the lymphocyte micronucleus assay. Int J Radiat Biol 2000; 76:1617-1619
16. Wood RD, Mitchell M, Lindahl T. Human DNA repair genes, 2005. Mutat Res 2005;577:275-283
17. Wood RD, Mitchell M, Sgouros J, LindahlT. Human DNA repair genes. Science 2001;291:1284-1289
18. De la Torre C, Pincheira J, Lopez-Saez JF. Human syndromes with genomic instability and multiprotein machines that repair DNA double-strand breaks. Histol Histopathol 2003;18:225-243 (Pubitemid 36040464)
19. O'Driscoll M, Cerosaletti KM, Girard PM, et al. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol Cell 2001;8:1175-1185 (Pubitemid 34084990)
20. Gutierrez-Enriquez S, Fernet M, Dork T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004;40:109-119 (Pubitemid 38579879)
21. Andreassen CN, Alsner J, Overgaard J. Does variability in normal tissue reactions after radiotherapy have a genetic basisOwhere and how to look for it? Radiother Oncol 2002;64:131-140
22. Angele S, Romestaing P, Moullan N, et al. ATM haplotypes and cellular response to DNA damage: association with breast cancer risk and clinical radiosensitivity. Cancer Res 2003;63:8717-8725 (Pubitemid 38064049)
23. Cesaretti JA, Stock RG, Lehrer S, et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int JRadiat Oncol Biol Phys 2005;61:196-202. (Pubitemid 40039123)
24. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS. ATM mutations in female breast cancer patients predict for an increase in radiationinduced late effects. Int J Radiat Oncol Biol Phys 2002;52:606-613 (Pubitemid 34158720)
25. Hall EJ, Schiff PB, Hanks GE, et al. A preliminary report: frequency of A-T heterozygotes among prostate cancer patientswith severe late responses to radiation therapy. Cancer J Sci Am 1998;4:385-389
26. Andreassen CN, Overgaard J, Alsner J, et al. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Int JRadiat Oncol Biol Phys 2006;64:776-783 (Pubitemid 43183574)
27. West CM, Elliott RM, Burnet NG. The genomics revolution and radiotherapy. Clin Oncol (R Coll Radiol) 2007;19:470-480
28. Andreassen CN, AlsnerJ, Overgaard M, Overgaard J. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003;69:127-135 (Pubitemid 37485871)
29. Damaraju S, Murray D, Dufour J, et al. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006;12:2545-2554
30. Suga T, Iwakawa M,Tsuji H, et al. Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2008;72:808-813
31. Bentzen SM. Preventing or reducing late side effects of radiation therapy: radiobiology meetsmolecular pathology. Nat Rev Cancer 2006;6:702-713
32. Spycher C, Miller ES,Townsend K, et al. Constitutive phosphorylation of MDC1 physically links the MRE11-50-NBS1 complex to damaged chromatin. JCell Biol 2008;181:227-240 (Pubitemid 351574549)
33. Wang Y, Cortez D,Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex ofBRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-939 (Pubitemid 30253002)
34. Robins P, Lindahl T. DNA ligase IV from HeLa cell nuclei. J Biol Chem1996;271:24257-24261
35. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31:1341-1346
36. Barry MJ, Fowler FJ, Jr., O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of theAmerican Urological Association. J Urol 1992;148:1549-57; discussion 64.
37. Pugh TJ, Bebb G, Barclay L, et al. Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients. BMC Cancer 2007; 7:128. (Pubitemid 47337236)
38. Olive PL, Banath JP, Keyes M. Residual gH2AX after irradiation of human lymphocytes and monocytes in vitro and its relation to late effects after prostate brachytherapy. Radiother Oncol 2008;86: 336-346 (Pubitemid 351335443)
39. Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A 1992;89:10915-10919
40. Eddy SR. Where did the BLOSUM62 alignment score matrix come from? Nat Biotechnol 2004;22: 1035-1036
41. Meyer A, Wilhelm B, Dork T, et al. ATM missense variant P1054R predisposes to prostate cancer. Radiother Oncol 2007;83:283-288 (Pubitemid 46915548)
42. Parmley JL, Hurst LD. How do synonymous mutations affect fitness? Bioessays 2007;29:515-519